Impact on healthcare stocks post-PBM Act decision by end of 2025
Significant increase (>10%) • 25%
Moderate increase (0-10%) • 25%
No change or decrease • 25%
Significant decrease (>10%) • 25%
Stock market data and financial reports from major financial news outlets
Senators Warren and Hawley Lead Bipartisan Bill to Force PBMs to Divest Pharmacies in 3 Years
Dec 11, 2024, 05:00 PM
A bipartisan group of U.S. lawmakers, led by Senators Elizabeth Warren and Josh Hawley, has introduced legislation aimed at addressing conflicts of interest within the pharmaceutical industry. The proposed bill, known as the Patients Before Monopolies (PBM) Act, would require pharmacy benefit managers (PBMs) and health insurers to divest their ownership of pharmacies within three years. This move is intended to curb the influence of PBMs, which have been accused of manipulating the market, inflating drug prices, and driving small pharmacies out of business. The legislation has garnered support in both the Senate and the House, with Representatives Diana Harshbarger and Jake Auchincloss introducing a companion bill in the House. The bill seeks to establish a firewall within the prescription-drug supply chain, separating those who research, manufacture, prescribe, and dispense drugs from those who manage benefits and insurance. The initiative has led to a decline in health care stocks as investors react to potential changes in business models, particularly affecting companies like CVS Caremark and OptumRx.
View original story
Pharmaceuticals • 25%
Healthcare • 25%
Consumer Goods • 25%
Technology • 25%
Other • 25%
Novo Nordisk • 25%
Bristol-Myers Squibb • 25%
Amgen • 25%
Severe financial penalties • 25%
Major financial penalties • 25%
No significant impact • 25%
Minor financial penalties • 25%
Mixed opinions • 25%
More negative • 25%
Unchanged • 25%
More positive • 25%
Cigna’s Express Scripts • 33%
UnitedHealth’s OptumRx • 33%
None • 1%
CVS Health’s Caremark • 33%
Increases by up to 5% • 25%
Increases by more than 5% • 25%
Decreases • 25%
No significant change • 25%
Policy changes mandated • 25%
No action taken • 25%
Fines imposed • 25%
Other outcomes • 25%
Cigna's Express Scripts • 25%
No penalties by end of 2025 • 25%
CVS Health's Caremark • 25%
UnitedHealth Group's OptumRx • 25%
Pfizer • 25%
Novo Nordisk • 25%
GlaxoSmithKline • 25%
Other • 25%
Underperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Outperforms the biotech index • 25%
Highly volatile with no clear trend • 25%
Not passed • 25%
Passed both Houses • 25%
Passed only in Senate • 25%
Passed only in House • 25%